Trial Profile
A Phase 4 Multicenter, Randomized, Double Blind Study to Describe the Efficacy and Safety of Cubicin (Daptomycin for Injection) With and Without Initial Gentamicin Combination Therapy in the Treatment of S. Aureus Infective Endocarditis.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 13 Dec 2023
Price :
$35
*
At a glance
- Drugs Daptomycin (Primary) ; Gentamicin
- Indications Bacterial endocarditis; Staphylococcal infections
- Focus Pharmacodynamics
- Sponsors Cubist Pharmaceuticals
- 22 Nov 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 15 Nov 2011 Planned end date changed from 1 Feb 2013 to 1 Nov 2011 as reported by ClinicalTrials.gov.
- 15 Nov 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.